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Despite symptom assessment serving as one of the primary aspects of management for atrial 
fibrillation, no standardized instrument for documenting symptoms exists.  The purpose of this 
project is to further assess the utility of the Canadian Cardiovascular Society Severity of Atrial 
Fibrillation (CCS-SAF) scale within the subspecialty of electrophysiology at the Minneapolis 
Heart Institute.  The target population is physicians, nurse practitioners, and physician assistants 
within the subspecialty electrophysiology evaluating patients in the clinic setting.  Before scale 
implementation, dissemination of information regarding the scale occurred through an 
educational session and pre-implementation survey.  Following an implementation period of six 
weeks, a post-implementation survey was completed to identify the value of a symptom severity 
scale.  Participation in the post-implementation survey was 54%.  The CCS-SAF scale improved 
communication and assisted with assessing response to therapy; however, utility of the scale for 
treatment decisions was equivocal.  A significant factor limiting integration of the scale into 
documentation was the absence of an automated process.  Based on these findings, creation of a 
system-wide SmartText is occurring to enhance scale use.  With consistent use, the goal is the 
scale will permeate not only the subspecialty of electrophysiology but general cardiology, 
additional cardiovascular subspecialties, internal medicine, and family practice as well.  Through 
ongoing use of the scale, there will be less variation in the assessment of atrial fibrillation, and 
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Implementing an Atrial Fibrillation Symptom Severity Scale within the Subspecialty of  
 
Electrophysiology at the Minneapolis Heart Institute  
 
 Chronic conditions are increasing in prevalence across the United States, significantly 
contributing to morbidity and mortality (Centers for Disease Control and Prevention [CDC], 
2018).  Atrial fibrillation, the most prevalent arrhythmia encountered in clinical practice (Ha et 
al., 2014) and leading cause for arrhythmia-related hospitalizations (Heidt et al., 2016; Sheikh et 
al., 2015), is one example of a chronic illness that affects numerous individuals.  The aging 
population and rise in risk factors such as hypertension and heart disease are some of the major 
contributing factors for the increasing prevalence of atrial fibrillation (Fosbol et al., 2013; 
Proietti et al., 2017).  
 As the number of individuals with atrial fibrillation increases, so do costs, morbidity, and 
mortality.  According to Sheikh et al. (2015), when comparing hospitalization costs for 
individuals with and without a history of atrial fibrillation, those with a history of atrial 
fibrillation have expenses approximately three times higher than those without this diagnosis.  
Expenditures surrounding atrial fibrillation are high, costing the health care system in the United 
States nearly six billion dollars annually (CDC, 2017).   
 More concerning than the financial burden of atrial fibrillation is the increase in 
morbidity and mortality.  “AF [atrial fibrillation] is independently associated with a two-fold 
increased risk of all-cause mortality in women and a 1.5-fold increase in men” (European 
Society of Cardiology [ESC], 2016, p. 2899).  Across the nation, atrial fibrillation contributes to 
approximately 130,000 deaths annually (CDC, 2017).  Despite technological advances for the 
identification and treatment of atrial fibrillation, death rates linked to atrial fibrillation have been 
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rising for the past 20 years (CDC, 2017) and the related morbidity and mortality remain 
unacceptably high (Kirchhof et al., 2016).  
Problem Formation  
Background 
 Given the increasing prevalence, high costs, morbidity, and mortality associated with 
atrial fibrillation, appropriate management is critical (Fosbol et al., 2013).  Health care providers 
play an integral role in this challenge.  When managing atrial fibrillation, a major focus is 
associated symptoms.  According to Zimmerman et al. (2016), “assessing and measuring 
symptoms is the basis for triage, diagnostic testing, and treatment and so is a priority for patients, 
clinicians, and researchers” (p. 475).  Reducing the symptom burden associated with atrial 
fibrillation not only improves quality of life but assists with lowering morbidity and mortality as 
well (Heidt et al., 2016).   
 Despite recommendations from the European Society of Cardiology (2016), American 
Heart Association, American College of Cardiology, and Heart Rhythm Society (2014) to assess 
symptoms prior to initiation of treatment for atrial fibrillation, consistency is lacking.  
Differences exists among both assessment and treatment of atrial fibrillation.  “Large variation in 
therapeutic approach suggests that there may be a substantial proportion of patients lacking 
treatment that can significantly improve quality of life” (Gehi et al., 2017, p. 95).   One method to 
reduce practice variation is through adoption of quality improvement tools (Gehi et al., 2017).  
An example of a quality improvement tool is a disease-specific, symptom severity scale.  
Consistent assessment and documentation of symptoms related to atrial fibrillation through use 
of a symptom severity scale will provide further clinical data.  This information can be utilized to 
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reach a collaborative decision regarding the best management strategy based on quality of life, 
guideline recommendations, and evidence-based practice.   
 Not only do disease-specific symptom scales assist with quantifying the impact of atrial 
fibrillation (Heidt et al., 2016), they also help identify suboptimal management.  In a study by 
Freeman et al. (2015), use of a disease-specific, provider-administered symptom scale revealed 
61.8% of individuals with atrial fibrillation had symptoms, with 16.5% having severe or 
disabling symptoms.  Fabritz et al. (2017) noted that despite adequate rate control, approximately 
half of the individuals remained symptomatic.  In further research by Proietti et al. (2017), 25% 
of patients managed in a cardiology clinic were symptomatic at a two year follow up.  Given the 
high incidence of symptoms associated with atrial fibrillation, there is clear need to enhance 
management.  One aspect that can assist in this process is consistent application of a disease-
specific symptom severity scale in clinical practice.    
Problem Statement  
 Despite the presence of disease-specific instruments to assess atrial fibrillation severity, 
there is no consensus on what scale to use.  Without agreement, significant variation in the 
inclusion of symptoms will persist.  Comprehensive clinical evaluation for all individuals with 
atrial fibrillation assists with reducing adverse outcomes (Proietti et al., 2017).  By lowering 
variability and consistently implementing one disease-specific, provider-administered symptom 
severity scale across clinical practice, there will be less variation in assessment and enhanced 
management for individuals with atrial fibrillation.   
Needs Assessment   
 The working hypothesis was desire for a disease-specific, provider-administered 
symptom severity scale within the subspecialty of electrophysiology at the Minneapolis Heart 
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Institute would be high given management of a large number of individuals with a diagnosis of 
atrial fibrillation.  To further explore this need, creation of a pre-implementation survey took 
place.  Of the six respondents, 100% reported assessing and documenting symptoms for 
individuals with atrial fibrillation (SurveyMonkey, 2017).  No respondents indicated use of a 
symptom scale, although 100% felt it would be helpful (SurveyMonkey, 2017).   
Significance and Contribution to the Literature  
 Assisting with the development of a treatment plan, assessing response to therapy, and 
enhancing communication are a few of the positive impacts consistent use of an atrial fibrillation 
severity scale can have.  By implementing one disease-specific symptom severity scale, the goal 
is to demonstrate these benefits.  If data supports the scale assists with the treatment plan, 
enhances communication, and helps assess response to therapy, professional organizations can 
utilize the information to reach a consensus on what scale to use.  Additionally, use of a 
symptom severity scale will provide further data for which providers can draw from to determine 
whether consultation would be beneficial.  Cardiology and electrophysiology input is valuable 
for many individuals with atrial fibrillation (Steinberg et al., 2013).  A patient-centered 
management plan established through specialty clinics, such as electrophysiology, results in a 
reduction in hospitalization for individuals with a diagnosis of atrial fibrillation (Tran et al., 
2013).     
Significance to the Nursing Profession  
 The effect of implementing a disease-specific symptom severity scale will be 
multifactorial, influencing all members of the care team, with the patient at the center.  As the 
electrophysiology team at the Minneapolis Heart Institute is an interdisciplinary group, all 
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members will contribute to implementation, ongoing utilization, and long-term efficacy of an 
atrial fibrillation symptom severity scale. 
 Nurses play an important role in the successful management of atrial fibrillation through 
triage calls and direct patient care.  Documentation of symptom severity through a disease-
specific instrument will assist with rapid identification of overall management.  This will be 
particularly helpful in situations where much of the interaction occurs over the phone.  Nurses 
within the electrophysiology team play a significant role in this aspect of management.    
 The interdisciplinary team of physicians, nurse practitioners, physician assistants, 
registered nurses, clinical assistants, genetic counselor, and coordinators that form the 
electrophysiology group work together with a clear, common goal to improve the quality of life 
for those served.  This team embodies interdisciplinary collaboration, which Petri (2010) 
describes as health care providers from different disciplines working collaboratively to provide 
high-quality, patient-centered care.  Interdisciplinary teams such as the electrophysiology group 
at the Minneapolis Heart Institute strive to attain these goals and data suggests these goals are 
becoming a reality.  In a study by Fumagalli et al. (2016) it was demonstrated that “…a 
multidisciplinary approach to AF [atrial fibrillation] management, covering all aspects of care, 
including baseline evaluation, education, therapy, and follow-up could significantly reduce the 
incidence of arrhythmia-related hospitalizations and of stroke” (p. 625).   
 Purpose Statement  
 Given the lack of consistency in assessing and documenting symptom severity in atrial 
fibrillation, there is desire to implement a disease-specific, provider-administered scale.  
Although a symptom severity scale will create a standardized method for documentation and put 
into context the impact atrial fibrillation has on quality of life (Dorian et al., 2009), utility in 
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clinical practice for the electrophysiology group at the Minneapolis Heart Institute for enhancing 
treatment decisions, communication, and evaluation remains unclear.  The purpose of this project 
is to investigate the following question: “For providers within the subspecialty of 
electrophysiology at the Minneapolis Heart Institute, what is the impact of a disease-specific 
symptom severity scale on communication, treatment, and evaluation in the management of atrial 
fibrillation?”    
PICO  
 Physicians, nurse practitioners, and physician assistants within the subspecialty of 
electrophysiology at the Minneapolis Heart Institute providing care for patients with a diagnosis 
of atrial fibrillation in the clinic setting comprise the population for this project.  The intervention 
involves implementation of a disease-specific symptom severity scale for patients with a 
diagnosis of atrial fibrillation.  The comparison is the current practice, which does not include 
use of a symptom severity scale.  Following application of the scale, a post-implementation 
survey will demonstrate the outcome by assessing the subjective impact on communication, 
treatment decisions, and evaluation. 
 There are several objectives and goals for this project, which not only guide 
implementation but assist with assessing scale utility as well.   
Objectives  
- Select a disease-specific symptom severity scale for implementation by the Summer of 
2017.  
- Complete staff education sessions in the Fall of 2017 with subsequent scale 
implementation.  
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- Achieve a 50% completion rate for qualifying patients with documentation of symptoms 
associated with atrial fibrillation and severity class during the implementation phase.  
- Analyze the quantitative and qualitative data in the Winter of 2018 to further identify 
trends and feasibility of dissemination.  
- Establish recommendations for ongoing use of the symptom severity scale by the Spring 
of 2018.  
Goals  
- Implement a symptom severity scale within the subspecialty of electrophysiology at the 
Minneapolis Heart Institute.  
- Consistent application of a symptom severity scale during initial and follow up visits for 
patients with a primary visit diagnosis of atrial fibrillation.   
- Disseminate the scale to general cardiology, additional cardiovascular subspecialties, 
internal medicine, and family practice within Allina Health.   
Theoretical Framework  
 Nursing theory plays an important role in clinical practice, research, and providing 
direction for a project (Moran, Burson, and Conrad, 2017).  Application of the University of 
California San Francisco symptom management theory helped to explore the proposed 
intervention.   
Symptom Management Theory  
 The symptom management theory is a middle range theory first introduced in 1994 by 
faculty at the University of California, San Francisco School of Nursing.  This theory “…serves 
to guide symptom assessment and treatment in nursing practice and to suggest questions and 
hypotheses for nursing research” (Humphreys et al., 2014, p. 141).  The symptom management 
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theory is applicable to the intervention of a disease-specific symptom severity scale as both the 
theory and scale focus on the interplay between symptoms and impact on functional status and 
quality of life (Dorian et al., 2009; Humphreys et al., 2014).   
 As with many theories in nursing, the symptom management theory utilizes a holistic 
approach.  Surrounding the primary concepts of symptom experience, management, and 
outcomes are the larger spheres of person, environment, and health and illness (Humphreys et al., 
2014).  A similar comprehensive approach is necessary for application of a symptom severity 
scale as not only do symptoms need to be brought to light but so do the possible adverse effects 
from treatment and overall functional impact atrial fibrillation is having on the individual.   
 The symptom management theory will guide one of the goals of the symptom scale; 
assessing response to therapy.  According to Humphreys et al. (2014), the impact of an 
intervention on symptoms is clear and measurable.  Additionally, “…improvement in symptoms 
can lead to better physical and mental functioning, improved quality of life, shorter hospital stay, 
quicker return to work, and greater productivity, all with less cost to the individual, family, and 
health care system, or employer” (Humphreys et al., 2014, p. 145).  Through enhanced symptom 
assessment, the potential for downstream reduction in health care expenditure exists and should 
be a focus for all members of society as we strive to be stewards of health equity and social 
justice.  
 Following identification of a nursing theory to help clarify the intervention, a theory to 
guide implementation of the symptom severity scale was needed.  This process led to 
identification of a theory grounded in the discipline of social science.   
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Diffusion of Innovation Theory 
 Rogers’ diffusion of innovation theory explains how, “…over time, an idea or product 
gains momentum and diffuses (or spreads) through a specific population or social system” 
(Boston University School of Public Health, 2016, para 1).  A goal surrounding implementation 
of a symptom severity scale within the subspecialty of electrophysiology is that it will become a 
standard of practice among the providers in the group.  To achieve this goal, the diffusion of 
innovation theory outlines the differing adopters and factors impacting the success of 
implementation.   
 The major concept of the diffusion of innovation theory centers around the stages of 
adopters and their impact on change.  There are five categories of adopters, all of which are 
important for effective implementation.  Rogers (2003) identifies the following five categories of 
adopters: innovators, early adopters, early majority, late majority, and laggards.  When adopters 
are divided into groups and graphed it reflects that of normal distribution (Rogers, 2003).   
 Innovators are individuals viewed as risk takers who are willing to venture outside the 
status quo (Rogers, 2003).  Innovators are important when implementing change as they are the 
individuals who embrace the idea, assisting with introduction to others (Rogers, 2003).  Early 
adopters comprise the next group.  They play an essential role in the overall diffusion process as 
they are leaders and their acceptance encourages further adoption (Rogers, 2003).   
 The next group of adopters is the early majority, comprising one of the largest categories 
at 34% (Rogers, 2003).  This group spends time analyzing the proposal and after contemplation, 
embrace the change (Rogers, 2003).  Once this group adopts, critical mass occurs.  Rogers 
(2003) describes critical mass as “…the point at which enough individuals in a system have 
adopted an innovation so that the innovation’s further rate of adoption becomes self-sustaining” 
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(p. 343).  Reaching critical mass is not only important for successful implementation of the scale 
among the subspecialty of electrophysiology but further dissemination outside of this group as 
well.  
 Late majority and laggards make up the remaining 50% of adopters (Rogers, 2003).  The 
late majority are uncertain about a proposal and wait for the majority to adopt before committing 
(Rogers, 2003).  The laggards make up the final portion.  This group of individuals tend to 
support the status quo and need further time to process their decision before committing (Rogers, 
2003).  
 In addition to providing framework for scale implementation, the diffusion of innovation 
theory serves as a foundation for developing expectations.  If one knows in advance that some 
individuals will be eager to participate, while others less so, it assists with developing a strategy 
to encourage involvement.  It also gives the primary investigator realistic expectations for 
participation and the change process.   
 The diffusion of innovation theory also provides a foundation for the factors which will 
enhance success.  Through demonstration of the advantage, compatibility with practice, 
simplicity of use, and outcomes (Rogers, 2003), the likelihood of successful diffusion of the 
scale will increase.  
 Throughout the diffusion of innovation theory is the foundation of communication 
(Kaminski, 2011).  Lack of communication will stifle the diffusion process.  Communicating 
with those involved will increase their knowledge and assist with spreading news throughout the 
group (Kaminski, 2011).  This aspect is incredibly important as it contributes to the overall 
efficacy of the diffusion process throughout the differing adopter categories. 
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Literature Review  
Search Process 
 Review of CINAHL, PubMed, and the Cochrane Library assisted with identifying atrial 
fibrillation symptom severity scales.  Search terms were symptoms, symptom management, 
symptom severity, symptom severity scale, and quality of life.  Following identification of the 
search terms, pairing with atrial fibrillation occurred in the advanced search section.  
 Initially, exploration of publications within the last 10 years took place.  However, 
following further analysis, publication dates were limited to the past five years in the PubMed 
database.  This limiting criterion was applied secondary to the high number of similar articles 
and large number of results with use of a 10-year publication range.   
 Application of peer-reviewed, academic journals, English language, and major headings 
criteria took place to identify the most relevant data in CINAHL.  With exploration of the 
PubMed database, limiting criteria applied were free full text, review, and clinical trial.  Given 
the low number of results, application of limiting criteria in the Cochrane Library database did 
not occur.    
 The initial search process revealed 17 relevant articles.  However, after further review, 
six were excluded as they did not address the intervention.  The 11 articles included in the 
appraisal evaluated or employed a disease-specific symptom scale for atrial fibrillation.  The 
Johns Hopkins Research and Non-Research tools assisted with the appraisal process.  For further 
detail on the search strategy, refer to Appendix A.   
Appraisal 
 Application of the Johns Hopkins Non-Research Evidence Tool (2013) helped with the 
appraisal of the literature review and practice guideline.  Evidence level for the literature review 
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by Aliot, Botto, Crijns, and Kirchhof (2014) is V and quality high (A), with expertise, clear 
conclusions, and rationale for further exploration of quality of life in individuals with atrial 
fibrillation.  Evidence level for the clinical practice guideline by the European Society of 
Cardiology (2016) is IV and quality high (A) secondary to release by a professional agency and 
identification of class and level for recommendations.   
 For the remainder of the studies, the Johns Hopkins Research Evidence Appraisal Tool 
(2013) was the hierarchy applied to clarify evidence level.  Following identification of the 
evidence level, application of the Critical Appraisal Skills Programme (2017) assisted with 
reaching a quality rating.  There was one evidence level I study.  Although high in evidence, the 
randomized controlled trial by Bowyer et al. (2017) has a quality rating of good (B) secondary to 
limited internal validity (inadequate number included in the control group and no masking of 
participants, researchers, or evaluators).    
 Evidence level III, non-experimental research, represents the remaining eight articles in 
the appraisal.  The research by Freeman et al. (2015), Ha et al. (2014), Nazli et al. (2016), and 
Wynn et al., (2014) are high quality (A) due to detailed explanation of methods, results, and clear 
identification of limitations.  Additional advantages of the study by Freeman et al. (2015) and Ha 
et al. (2014) are the number of patients and multiple locations.  These aspects increase both 
transferability and generalizability of findings.   
 The remaining evidence level III studies are good quality (B).  Results from Koci et al. 
(2014) have limited transferability as implementation occurred at one center on one patient 
population.  Chiang et al. (2016) did not include a detailed discussion of the measurement tool, 
reducing quality.  The study by King et al. (2015) noted, “…patients derive significant symptom 
relief following rate control or rhythm control therapy” (p. 690), yet one of the limitations is a 
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possible placebo effect.  Vermond et al. (2014) thoroughly describe the purpose, methods, and 
results in their study.  With the post hoc design, however, it is difficult to claim a clear 
association between symptom severity in atrial fibrillation and adverse cardiovascular outcomes.  
For further detail regarding the individual evidence summary tool for each article, refer to 
Appendix B.    
Synthesis  
 Much of the research surrounding symptom scales did not directly focus on the 
instrument but rather used a scale to assess response to interventions or quantify the impact atrial 
fibrillation has on an individual’s quality of life.  Both generic and disease-specific scales were 
employed.  Aliot et al. (2014) note the German Competence Network on Atrial Fibrillation and 
the European Heart Rhythm Association “recommend the design, validation, and further use of 
AF-specific instruments to assess AF-related QoL [quality of life], particularly when 
improvement of symptoms and QoL are the desired primary outcomes” (p. 788).  
 There is little data to support use of one disease-specific scale over another.  Two of the 
more prevalent instruments, the Canadian Cardiovascular Society Severity of Atrial Fibrillation 
(CCS-SAF) scale and the European Heart Rhythm Association (EHRA) classification are 
recommended for clinical use by their respective professional organizations, the Canadian 
Cardiovascular Society and the European Society of Cardiology (Ivers & Dorian, 2014; ESC, 
2016).  Both of these instruments use a numeric scale for classification and are provider-
administered.  The CCS-SAF scale uses a 0-4 rating, with class 0 being no symptoms related to 
atrial fibrillation and class 4 representing severe effect on quality of life from atrial fibrillation 
symptoms (Dorian et al., 2009).  The EHRA classification rates symptoms on a 1-4 scale, with 1 
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representing no symptoms from atrial fibrillation and 4 being disabling symptoms secondary to 
atrial fibrillation (ESC, 2016).    
 In their 2015 research, Freeman et al. assess symptom severity and quality of life for 
individuals with a diagnosis of atrial fibrillation.  For this analysis, the EHRA classification scale 
quantifies symptom severity.  The EHRA provides a means for clearly demonstrating the high 
percentage (61.8%) of individuals with atrial fibrillation who remain symptomatic (Freeman et 
al., 2015).  Additionally, for this study, values from the EHRA were compared to the valid, 
reliable, and responsive patient completed questionnaire on quality of life, the Atrial Fibrillation 
Effect on Quality-of-Life (AFEQT) (Freeman et al., 2015; Zimmerman et al., 2016).  Following 
analysis, a higher EHRA classification score correlated with lower scores on the AFEQT 
questionnaire (Freeman et al., 2015).  This finding indicates that not only does the EHRA scale 
assist with evaluating symptom severity but quality of life for patients as well (Freeman et al., 
2015).  
 As use of the EHRA classification scale increased, there was desire to enhance the ability 
for the scale to discern a clear difference between mild to moderate symptoms (Wynn et al., 
2014).  To further address this, Wynn et al. (2014) proposed a modification to the scale by 
dividing class 2 into 2a and 2b.  Through further evaluation, there was a significant difference in 
level of impact of symptoms (Wynn et al., 2014).  Given this, proposal of a modified version of 
the EHRA (mEHRA) ensued.  The AFEQT was again utilized for comparison to achieve 
validity.  Following review of the data, a clear trend toward lower quality of life scores 
correlated with higher mEHRA classification (Wynn et al., 2014).  Subsequently, the European 
Society of Cardiology adopted the modified version as the preferred scale for use.  
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 The remaining articles employing a disease-specific instrument focus on the CCS-SAF 
scale.  Ha et al. (2014), in their observational cohort sub-study, assess quality of life for patients 
with atrial fibrillation when pursuing a rate or rhythm control strategy.  Patients complete the 
disease-specific, University of Toronto Atrial Fibrillation Severity Scale (AFSS).  Comparison 
between the results of the AFSS and the CCS-SAF scale then took place, demonstrating the 
utility of the CCS-SAF scale as a standardized measure (Ha et al., 2014).  As the CCS-SAF class 
increases, the AFSS score also rises, demonstrating a linear correlation (Ha et al., 2014).  
 In the 2015 study completed by King et al., the CCS-SAF scale quantified symptom 
severity for patients with minimally symptomatic atrial fibrillation.  Following evaluation, even 
patients with a perception of low symptom burden benefit from further treatment as the true 
extent of their symptoms were more clearly demonstrated following application of the CCS-SAF 
scale (King et al., 2015).  The CCS-SAF scale can serve as a useful tool for identifying 
previously asymptomatic individuals (King et al., 2015), particularly those of advanced age, as 
they often place less emphasis on their symptoms (Heidt et al., 2016).     
 Nazli et al. (2016) utilize both the EHRA classification and CCS-SAF scale in their 
study.  The CCS-SAF served to quantify the functional impact of symptoms related to atrial 
fibrillation and the effects on quality of life (Nazli et al., 2016).  Application of the EHRA 
classification assisted with identifying the functional consequences of atrial fibrillation (Nazli et 
al., 2016).  Both scales helped with the conclusions of the study, which indicated that patients 
with atrial fibrillation have a high symptom burden as well as impaired quality of life, 
particularly those with paroxysmal atrial fibrillation (Nazli et al., 2016). 
 Although non-research has a lower evidence level on the Johns Hopkins Non-Research 
Tool (2013), the clinical practice guideline by the European Society of Cardiology and the 
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literature review by Aliot et al. (2014) assisted with further exploration of the topic of interest.  
The European Society of Cardiology recommends use of the mEHRA classification scale when 
assessing patients with atrial fibrillation with a Class I, Level C recommendation.  The mEHRA 
classification scale can “…guide symptom-orientated treatment decisions” and allow for long-
term monitoring (ESC, 2016, p. 2907).   
 In the literature review by Aliot et al. (2014), evaluation of both generic and disease-
specific scales for assessing quality of life occurred.  Although the future role for disease-
specific instruments such as the CCS-SAF scale and EHRA classification are unclear, both 
demonstrate utility for assessing the impact of symptoms and selecting treatments for individuals 
with atrial fibrillation (Aliot et al., 2014).   
Evidence to Support Intervention 
 Consensus does not exist across the professional organizations on which provider-
administered symptom severity scale to employ when assessing individuals with atrial 
fibrillation.  Of the articles included in the literature review, only the study by Nazli et al. (2016) 
includes both the CCS-SAF scale and EHRA classification.  Despite inclusion of both, there was 
no comparison between utility in clinical practice.  
 Use of the CCS-SAF scale occurred in the evidence level III, high quality research by Ha 
et al. (2014) and the evidence level III, good quality research by King et al. (2015).  Use of the 
EHRA/mEHRA took place in the evidence level III, high quality studies completed by Wynn et 
al. (2014) and Freeman et al. (2015).  The EHRA/mEHRA was validated through comparison to 
the AFEQT, which is one of the few scales with not only validity and reliability but 
responsiveness as well (Zimmerman et al., 2016).  Given this data, the decision was made to 
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implement the mEHRA classification scale within the subspecialty of electrophysiology at the 
Minneapolis Heart Institute.   
 Shortly after identifying the desired scale, a research study, which included one of the 
team members in the electrophysiology group, was using an alternative disease-specific, 
provider-administered severity scale.  The focus of the study was to evaluate the safety and 
efficacy of a specific catheter for patients with symptomatic, persistent atrial fibrillation 
(Minneapolis Heart Institute Foundation®, 2017a).  The relevance of this research on the 
proposed intervention was use of the CCS-SAF scale to document symptom severity for patients.  
Following further consideration, the decision was made to implement the CCS-SAF scale rather 
than the mEHRA classification.  Given identification of a specific instrument, a focused 
literature review on the CCS-SAF scale ensued.   
Focused Literature Review 
Search Process 
 Exploration of the PubMed database occurred for further research on the validity and 
utility of the CCS-SAF scale.  CINAHL was briefly evaluated with no new relevant articles 
identified.  Search terms included: symptom scale AND atrial fibrillation, Canadian 
Cardiovascular Society AND atrial fibrillation, Canadian Cardiovascular Society AND severity 
of atrial fibrillation, and symptom instrument AND cardiovascular.  There were minimal 
restrictions given the specificity of the searches.  One additional search for the most up to date 
information following the initial literature review performed in the spring of 2017 occurred in the 
winter of 2018.  This search involved the broad search terms symptoms AND atrial fibrillation.  
Restrictions included review, date range from 2016-2017, and free full-text secondary to the 
expansive nature of the search.   
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 Initial evaluation revealed 13 articles.  After analysis of the abstracts, four articles met 
relevant criteria.  The Johns Hopkins Research and Non-Research tools assisted with the 
appraisal process.  For further detail on the focused search strategy, refer to Appendix C.   
Synthesis  
 The CCS-SAF scale was first proposed in the consensus statement released by Dorian et 
al. in 2006.  Rationale for the creation and use of the scale was to quantify symptoms related to 
atrial fibrillation in a standardized fashion, which could ultimately improve patient care through 
facilitating treatment decisions and enhancing communication among the health care team 
(Dorian et al., 2006).   
 The 2009 research article by Dorian et al. validated the CCS-SAF scale.  In this study, 
correlation existed between the CCS-SAF scale, the generic 36-Item Short Form Health Survey 
(SF-36), and disease-specific AFSS.  There was an inverse association between the CCS-SAF 
and SF-36 and a parallel relationship with the AFSS (Dorian et al., 2009).  In addition to 
assessing symptom severity, the CCS-SAF scale places into context the impact treatments have 
on quality life and is not exclusive to arrhythmia episodes (Dorian et al., 2009).       
 The literature review by Heidt et al. (2016) addressed the utility of the CCS-SAF in 
clinical practice, noting similar findings as to those addressed in the study by Dorian et al. 
(2009).  Discussion of the mEHRA also took place, but comparison between the two scales did 
not occur.  Heidt et al. (2016) speculate “…the EHRA, mEHRA, and CCS-SAF scales will 
become commonplace in clinical practice” (p. 86).   
 Zimmerman et al. (2016), in their literature review, note the CCS-SAF incorporates 
multiple symptoms, is multi-dimensional, specific, and demonstrates validity.  The CCS-SAF 
measures symptoms attributed to and associated with atrial fibrillation in addition to therapies 
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with their possible consequences, helping to capture all components of the condition (Dorain et 
al., 2009; Zimmerman et al., 2016).  Some of the limitations of the scale are lack of reliability 
given the subjective nature of the scale (provider-administered) and lack of responsiveness 
(Zimmerman et al., 2016).     
 To reduce confusion for this project, the decision was made to move forward with 
implementation of the CCS-SAF.  Logistically, having two scales would further impair 
successful implementation.  Following further review, the CCS-SAF was the best option for 
implementation among the group as it is valid, easy to apply, captures all aspects of atrial 
fibrillation, and is not exclusive to arrhythmia episodes (Dorian et al., 2006; Dorian et al., 2009; 
Heidt et al., 2016; Zimmerman et al., 2016).   
 One constant in both the initial and focused literature review is the lack of data 
comparing scales in an attempt to demonstrate superiority.  Although the 2014 practice 
guidelines from the American Heart Association, American College of Cardiology, and Heart 
Rhythm Society recommend assessing symptoms associated with atrial fibrillation during initial 
and subsequent evaluation, no scale is endorsed.  For further detail on the individual evidence 
summary tool, refer to Appendix D. 
Project Implementation 
 The intervention for this project is implementation of the CCS-SAF scale within the 
subspecialty of electrophysiology at the Minneapolis Heart Institute.  Following evaluation of the 
data, the objective is to answer the following question, “For providers within the subspecialty of 
electrophysiology at the Minneapolis Heart Institute, what is the impact of a disease-specific 
symptom severity scale on communication, treatment, and evaluation in the management of atrial 
fibrillation?”    




 Stakeholders for implementation of an atrial fibrillation symptom scale within the 
subspecialty of electrophysiology include: physicians, nurse practitioners, physician assistants, 
registered nurses, clinical assistants, clinic coordinators, clinic managers, and individuals 
evaluated within the clinic with a diagnosis of atrial fibrillation.  Pending results for this group, 
stakeholders may broaden to include internal medicine and primary care providers within Allina 
Health, organizational leaders, and patients served through the Allina Health System with a 
diagnosis of atrial fibrillation.   
Design  
 The CCS-SAF is a disease-specific, provider-administered scale for assessing symptom 
severity in atrial fibrillation first introduced in 2006 by Dorian et al.  Prior to moving forward 
with the project, email correspondence with Dr. Paul Dorian verified permission to use the scale 
within the clinic (refer to Appendix E for scale criteria and example).  Exploration online 
revealed a modified version of the CCS-SAF scale from the American College of Cardiology 
Foundation (2012).  This form is on one page and thus served as a guide for the project as it 
enhanced simplicity.  Before introducing the modified version, email communication with 
American College of Cardiology occurred to gain permission for clinic use (refer to Appendix F 
for example). 
 Implementation of the CCS-SAF scale is a quality improvement project, for which the 
plan, do, study, act (PDSA) cycles serve as the design method.  This approach is often 
implemented on a small scale with further application following analysis of findings (Chapman 
& Larson, 2016).  As the initial focus is on one group within the Minneapolis Heart Institute, the 
objective is to evaluate the outcomes and act on the third goal, dissemination of the scale. 
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 Release of an information sheet regarding further detail of the project (Appendix G) and 
the pre-implementation survey (Appendix H) transpired in November of 2017 following 
verification from the Allina Health and St. Catherine University Institutional Review Boards on 
quality improvement status of the project.  Two education sessions on different dates to further 
discuss the project purpose, goals, and objectives occurred.  For those unable to attend a session, 
a voiceover PowerPoint was available through email.  The presentation was available for 
physicians, nurse practitioners, physician assistants, registered nurses, clinical assistants, and 
schedule coordinators wishing to become familiar with the CCS-SAF scale.  The coordinators 
were encouraged to include the letters CCS-SAF in the notes section on the schedule for 
individuals with a diagnosis of atrial fibrillation.  To serve as a remainder during clinic visits, 
paper forms of the modified CCS-SAF scale created by the American College of Cardiology 
Foundation (2012) were made available.  Additionally, all potential participants had access to a 
dot phrase in the electronic health record created to further assist with documentation.  A 
recommendation by the primary investigator was to include the symptoms associated with atrial 
fibrillation and the CCS-SAF class in the physical exam section of the progress note.  The 
implementation period for application of the CCS-SAF scale occurred from December 18, 2017, 
through January 26, 2018.  Following this period, a post-implementation, online survey was sent 
to participants.  
Population  
 Physicians, nurse practitioners, and physician assistants within the electrophysiology 
group providing care to patients in the clinic setting with a diagnosis of atrial fibrillation 
comprised the population for the project.  This group is composed of nine physicians, four nurse 
practitioners, and two physician assistants.  Thirteen possible participants were available 
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following exclusion of the primary investigator and one nurse practitioner not involved with 
clinic evaluation.  Use of the scale was encouraged for all atrial fibrillation definitions noted in 
the 2014 American Heart Association, American College of Cardiology, and Heart Rhythm 
Society practice guideline (paroxysmal, persistent, long-standing persistent, and permanent).   
 There are a number of reasons why the providers within the subspecialty of 
electrophysiology at the Minneapolis Heart Institute serve as the focus population for scale 
implementation.  Not only are there a large number of individuals with atrial fibrillation 
evaluated on a weekly basis but additionally The Minneapolis Heart Institute has a partnership 
with the Minneapolis Heart Institute Foundation.  Collaboration between the Minneapolis Heart 
Institute and Minneapolis Heart Institute Foundation assists with translating research into 
practice (Minneapolis Heart Institute Foundation®,  2017b).  Given this partnership, research 
and innovation are highly valued and encouraged, making it an ideal organization and group for 
project implementation. 
Data Collection 
 An online survey, both pre and post-implementation, served as the data collection tool for 
evaluating the need and utility of the CCS-SAF scale.  The pre-implementation survey was open 
from November 27, 2017, through December 7, 2017, and the post-implementation survey 
January 30, 2018, through February 7, 2018.  To further assess overall use of the scale during the 
implementation phase, the primary investigator performed a review of the clinic schedule for all 
providers within the group and assessed charts for use of the CCS-SAF scale following closure 
of the post-implementation survey. 
Ethical Considerations  
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 On September 13, 2017, application to the Allina Health Institutional Review Board 
occurred, with verification of quality improvement project on November 16, 2017.  The St. 
Catherine University Institutional Board agreed with the classification of quality improvement 
project on November 19, 2017.   
 With use of the CCS-SAF scale, there is concern for variability in scoring due to the 
subjective nature of the class rating.  This lack of inter-rater reliability may result in variation 
between provider ratings.  A higher score indicates severe impact on quality of life (Dorian et al., 
2009) and aggressive treatment options, which subsequently have a higher risk for complication, 
may ensue.  Although this concern can not be fully mitigated given the subjective nature of the 
scale, the potential benefits of use are felt to outweigh the risks.  Furthermore, the modified scale 
provided by the American College of Cardiology Foundation (2012) has clear definitions for 
qualifying criteria for each classification.  
 Societal value for implementation of the CCS-SAF scale includes assessing and 
documenting symptom severity for all individuals with a diagnosis of atrial fibrillation, which is 
a cornerstone for management (Koci et al., 2014).  Symptom severity not only gives insight into 
the impact atrial fibrillation is having on quality of life but also assists with capturing 
“meaningful changes in a patient’s health status over time and more specifically after treatment 
interventions” (Koci et al., 2014, p. 261).  Research indicates aspects other than symptoms, 
quality of life, clinical impact, and patient preference drive decisions regarding the management 
of atrial fibrillation (Gehi et al., 2017).  Factors that often determine whether a rhythm strategy is 
pursued include evaluation by an electrophysiologist, private insurance coverage, and race (Gehi 
et al., 2017).  This deviation from guideline recommendations demonstrates an opportunity for 
decreasing variation in care and enhancing health care equity.  Although achieving health equity 
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requires numerous system-level changes, consistent implementation of a standardized symptom 
severity instrument such as the CCS-SAF scale represents one step in this direction.     
Evaluation   
 Following implementation of the CCS-SAF scale and closure of the post-implementation 
survey, data analysis took place.  Data consisted of both quantitative and qualitative responses.  
Of the 13 qualifying providers, seven completed the post-implementation survey in its entirety.  
One survey was partially complete and excluded from the analysis.  Based on the survey results, 
the CCS-SAF scale did not clearly assist with the treatment plan but did help with enhancing 
communication and assessing response to therapy (SurveyMonkey, 2018).  It was easy to use, 
and 57% of the respondents reported they would continue to use it (SurveyMonkey, 2018).  
 The qualitative, open-ended questions provided insight regarding the limitations of the 
scale.  A theme identified from the respondents, with approximately 67% noting this, was the 
absence of an automated method for scale integration into the electronic health record 
(SurveyMonkey, 2018).  One individual noted, “I think it’s a great idea to have a common way 
to assess symptoms.  The scale is fairly easy to use.  The toughest part is just remembering to do 
it” (SurveyMonkey, 2018, Q8, #4).  Another respondent indicated time as a barrier “…[the scale] 
would be more meaningful after longer follow-up periods (eg to assess trend in CCS-SAF scale 
after multiple follow-up visits/interventions)” (SurveyMonkey, 2018, Q8, #3).  For all post-
implementation survey questions and results, refer to Appendix I.  
 To further assess participation rate, a chart review for all patient visits during the 
implementation period of December 18, 2017 through January 26, 2018 took place.  Thirteen 
providers within the subspecialty of electrophysiology were included, covering four clinic 
locations.  Inclusion for chart review comprised primary visit diagnosis of atrial fibrillation, 
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CCS-SAF in the notes section, and all individuals with an unclear primary visit diagnosis.  Of the 
clinic visits evaluated in the specified time frame, 249 patients met criteria for completion of the 
CCS-SAF scale.  Following full review, documentation of the symptoms associated with atrial 
fibrillation and subsequent CCS-SAF scale classification occurred for 23 of the qualifying 
patients.  The overall completion rate was 9.2% of the qualifying individuals, failing to meet the 
pre-implementation objective of a 50% compliance rate.  For further detail on the chart analysis, 
refer to Appendix J.   
 Given the low participation rate, the overall utility of the CCS-SAF scale within the 
electrophysiology group at the Minneapolis Heart Institute remains unclear.  Based on the 
information from the survey respondents, the scale did assist with communication and assessing 
response to therapy.  A clear trend from the open-ended questions is the importance of an 
automated method for assessing and documenting symptoms and the CCS-SAF class for 
individuals with atrial fibrillation in the electronic health record.      
Limitations  
 A significant limitation of this project includes an unknown number of participating 
providers.  Consent was assumed if a provider completed the pre-implementation survey.  As 
participation was 50%, it is not clear whether the survey was not completed by the remaining 
individuals due to desire not to participate or for other reasons.  No clear method for providers to 
opt-out was available.  The number of patients qualifying for use of the CCS-SAF scale, 
therefore, may have been less if the provider was not participating yet the data analysis included 
patients from their schedule.  A way to remedy this issue moving forward is to have a clear opt-
out option on the pre-implementation survey.   
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 The time of year implementation occurred was another limitation for this project.  The 
initial target date for scale implementation was October 2017.  However, secondary to 
unforeseen delays, implementation did not take place until December 18, 2017.  This time of 
year presented a number of barriers.  One of the most significant being there were no clinic visits 
the week of December 25, 2017, through December 29, 2017.  Additionally, every qualifying 
provider was on vacation at some point throughout the implementation phase, impacting the 
ability to apply the scale on a consistent basis.  
 Not only was the time of year implementation took place a limitation, but so was the 
duration of implementation.  Of the individuals for which the scale was completed, 16 occurred 
in the last three weeks of implementation.  Based on this information, use of the scale was on the 
rise.  Given the limited length of time for project implementation, however, further progress 
toward achieving critical mass ceased.  Given the limited frequency of visits within the 
subspecialty of electrophysiology, an implementation period of at least one year would provide 
more useful data for further analysis of scale utility.   
 To assist with implementation, CCS-SAF was added to the notes section on the daily 
schedule prior to the visit.  This schedule is available for all providers in the electronic health 
record.  During the chart review process, CCS-SAF was not included in the notes section on a 
consistent basis until January 5, 2018.  This was another limitation as no qualifying patients had 
the scale added during six of the seven clinic days before inclusion of CCS-SAF in the notes 
section.  
 An additional limitation was the low use of the dot phrase created by the primary 
investigator.  Creation of a dot phrase (.CCSSAF) occurred prior to scale implementation to 
assist with use.  However, upon evaluation of the open-ended questions, it appears that many of 
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the providers were unaware of this option.  Furthermore, during the chart review process, only 
one of the 13 providers utilized the dot phrase.  This highlights the importance of ongoing 
communication throughout the change process and ensuring individuals have a clear 
understanding of the available tools.  
Discussion 
 When analyzing the data following implementation of the CCS-SAF scale within the 
subspecialty of electrophysiology, it is hard not to question whether symptom severity scales are 
worth the effort.  It is difficult to see the possible utility when results of a small-scale project 
reveal limited involvement.  When discouraging thoughts begin to arise, it is important to 
remember the purpose.  For this project, the aim is to increase symptom identification for those 
afflicted with atrial fibrillation.  Research consistently demonstrates an opportunity for 
enhancing management in atrial fibrillation with upwards of 50% of individuals remaining 
symptomatic (Freeman et al., 2015; Fabritz et al., 2016).  With review of the post-
implementation open-ended questions, the following statement brought the question of utility to 
light, “more guidelines [are] needed to connect scale with pathophysiology of disease” 
(SurveyMonkey, 2018, Q8, #1).  Without clear demonstration of utility, ongoing use of the sale 
appears ineffective.  However, without consistent implementation, the true clinical value can not 
be assessed.    
 One of the largest barriers at this time is the lack of consensus on what scale to use.  The 
European Society of Cardiology and Canadian Cardiovascular Society both recommend use of 
their respective scales when assessing individuals with atrial fibrillation (ESC, 2016; Ivers & 
Dorian, 2014).  To further address the lack of consensus, Koci et al. (2014) designed a new atrial 
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fibrillation classification scheme as there is a “…pressing need for a validated tool to assess AF-
specific patient-reported outcome” (p. 260).    
 One of the three aims, providing better care for the individual, and two of the six 
priorities, enhancing communication and promoting treatment of cardiovascular disease, 
identified by the Centers for Medicare and Medicaid Services (2016) are all potentially 
addressed with use of the CCS-SAF scale.  Two of the primary objectives of the scale are to 
assist with treatment decisions and communication (Dorian et al., 2006).  Data from this project 
indicates a positive impact on these aspects, with 71% of respondents noting enhanced 
communication and 57% of respondents reporting assistance with assessing treatment response 
(SurveyMonkey, 2018).   
 Another important aspect of health care is reimbursement.  With an ever-growing focus 
on value-based programs, outcomes and patient-experience play a crucial role in financial 
compensation.  Although all provider and patient completed symptom scales possess a subjective 
component, having a semi-quantitative value such as that provided by the CCS-SAF scale will 
assist with demonstrating outcomes.  Furthermore, if professional organizations in the United 
States follow that of the European Society of Cardiology and Canadian Cardiovascular Society, 
use of a scale will be an aspect of guideline-recommended practice.    
Recommendations  
 Although a majority of the providers anticipated benefit from scale use, participation was 
low, limiting the ability to assess overall utility.  One of the biggest aspects limiting ease of scale 
implementation was lack of an automated format such as SmartText.  SmartText are templates 
that “…insert a pre-created block of text to facilitate documentation of a note by quickly adding 
appropriate information” (Health Information Management, 2012, section 4).  Additionally, 
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SmartText allow for incorporation of wildcards, SmartLists, and SmartLinks (Health Information 
Management, 2012).  Furthermore, SmartText provide opportunity for data analysis as tracking 
of the entries can occur.    
 Due to lack of automation in the documentation process, the next step to further assess 
utility of the CCS-SAF scale is through creation of an Allina Health system-wide SmartText.  
Development of a SmartText did not occur at the onset of the project for two primary reasons; 
one being the unclear benefit of the scale and the other the length of time it takes to implement a 
system-wide SmartText, which can range from several months up to a year.  Although definite 
conclusions from the first cycle of the project cannot be made, 57% of the respondents indicated 
they would continue to use the scale (SurveyMonkey, 2018).  
 With creation of a CCS-SAF SmartText, the objective is to enhance integration of the 
scale into clinical practice.  Through consistent use, the goal is to achieve critical mass over time 
within the electrophysiology group.  With ongoing use, general cardiology, additional 
cardiovascular subspecialties, internal medicine, and family practice will become more familiar 
with the scale and if desired, will be able to easily integrate it for patients they care for with a 
diagnosis of atrial fibrillation.  Having this instrument readily available will allow for 
longitudinal monitoring and may also serve as a resource for referral to cardiology and 
electrophysiology.  
 In an era of technology, it is difficult to see the utility of a simple symptom severity scale.  
Applicability of symptom scales, however, should not be overlooked.  Likened to the New York 
Heart Association (NYHA) Functional Classification, atrial fibrillation severity scales may prove 
to have similar benefits going forward.  The NYHA Functional Classification is a powerful 
predictor of mortality for both systolic and diastolic heart failure (Ahmed, Aronow, & Fleg, 
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2006; Goode, Nabb, Cleland, & Clark, 2008).  Additionally, it has been around for many years, 
with the most recent update occurring in 1994, which was the 9th edition (American Heart 
Association, 2017).  Although patient completed scales are important, data demonstrates the 
NYHA Functional Classification given by the providers “…relates more strongly to survival and 
severity of left ventricular systolic dysfunction [than patient-reported NYHA Functional 
Classification], suggesting…the NYHA classification may have become a ‘heart failure severity 
score’” (Goode et al., 2008).  Given the provider-administered nature of the CCS-SAF scale, the 
utility for correlating the classification with not only atrial fibrillation symptom severity but 
morality may exist.  The only way to further explore the long-term utility of this scale is through 
consistent implementation across not only the subspecialty of electrophysiology but all practices 
who care for individuals with a diagnosis of atrial fibrillation.  
 Even if future research fails to demonstrate a correlation with the CCS-SAF scale and 
mortality, it will provide a method for ensuring similar assessment criteria for all patients with 
atrial fibrillation, regardless of treating provider specialty or clinic location.  Gehi et al. (2017) 
note significant practice variation regarding rhythm control management for atrial fibrillation, 
suggesting that factors other than patient symptoms and preferences are guiding treatment 
decisions.  Although the CCS-SAF scale does not provide recommendations for which treatment 
strategy to pursue for atrial fibrillation, it does provide a baseline.  If a patient is persistently 
falling into class 3 or 4 on the scale (moderate to severe impact on quality of life), this may 
prompt a change in the management approach or result in referral to cardiology or 
electrophysiology.   
 Future research directly comparing the available provider-administered scales is needed.  
This will help not only demonstrate possible advantages one has over another but will assist with 
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standardizing the language for symptom severity in atrial fibrillation as well.  For this project, 
the mEHRA classification was the original choice for scale implementation based on review of 
the literature.  However, given use of the CCS-SAF scale in a research study occurring at the 
same time through the Minneapolis Heart Institute Foundation, the CCS-SAF became the 
preferred scale.  Upon further review, the CCS-SAF scale was a better fit for a number of 
reasons, including ease of use, inclusion of all aspects of atrial fibrillation, and application 
outside arrhythmia episodes (Dorian et al., 2006; Dorian et al., 2009; Heidt et al., 2016; 
Zimmerman et al., 2016).  Although the CCS-SAF fit well for the first cycle of this project, 
further research and collaboration between the professional organizations are necessary to 
compare the available scales and reach consensus.   
Future Implications 
 As the age of individuals rises across the United States, so does the prevalence of chronic 
conditions such as atrial fibrillation (European Society of Cardiology, 2016).  Atrial fibrillation 
is the most common arrhythmia encountered in clinical practice (Ha et al., 2014) and 
independently increases morbidity and mortality in both women and men (European Society of 
Cardiology, 2016).  Given this data, adequate management is imperative.   
 Essential aspects in the management of atrial fibrillation include reducing symptom 
burden and enhancing consistency across practice.  The CCS-SAF scale serves as an example of 
a quality improvement tool providers can utilize to address these factors.  With a reduction in 
associated symptoms, quality of life for those affected with atrial fibrillation will improve and 
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1. CINAHL Symptom management 
AND atrial fibrillation (11) 
Publications since 2007 (9); peer 
reviewed (8); academic journals (8)  
8 1 
2. CINAHL Symptom severity AND 
atrial fibrillation (48) 
Publications since 2007 (29); peer 
reviewed (26); academic journals 
(26)   
26 5 
3. CINAHL  Symptom severity scale 
AND atrial fibrillation (4) 
None  4 1 
4. CINAHL Quality of life AND atrial 
fibrillation (643) 
Publications since 2007 (474); peer 
reviewed (460); academic journals 
(436); English language (434); 
major heading- atrial fibrillation 
(316); major heading- quality of life 
(97); publications since 2012 (51) 
51 3 
5. PubMed Symptom management 
AND atrial fibrillation (178) 
Publication dates- within 5 years 
(75); free full text (23) 
23 2 
6. PubMed Symptom severity AND 
atrial fibrillation (163)  
Publication dates- within 5 years 
(67); free full text (25) 
25 1 
7. PubMed Symptom severity scale 
AND atrial fibrillation (55) 
Publication dates- within 5 years 
(23); free full text (9) 
9 2 
8. PubMed Quality of life AND atrial 
fibrillation (1,588) 
Publication dates- within 5 years 
(637); free full text (246); review 
(56)  
56 1 
9. PubMed Quality of life AND atrial 
fibrillation (1,588)  
Publication dates- within 5 years 
(637); free full text (246); clinical 
trial (31) 





Symptom management and 
atrial fibrillation (3)  
None 3 0  
11. Cochrane 
Library  
Symptom severity and atrial 
fibrillation (2)   
None 2 0   
12. Cochrane 
Library  
Symptom severity scale and 
atrial fibrillation (24) 
None 24 1 new  
13. Cochrane 
Library  
Quality of life and atrial 
fibrillation (11)  
None 11 0 (no 
new 
articles)  
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Individual Evidence Summary Tool 
 
EBP Question: What are the Current atrial fibrillation disease-specific symptom severity 

















Sample Size & 
Setting 
Study findings that 












- Men (65.9%) 





with an average 
age of 62.1  
- 19 individuals 
in the control 
group and 22 in 
the intervention 
for a total of 41 
- Setting: 
Medical center 
in Australia  
- Short Form 36 (SF-36) 
utilized for quality of 
life 
- Symptoms measured 
through use of the AF 
Symptom Checklist, 
Frequency, and Severity 
scale  
- Based on SF-36 and 
AF Symptom Checklist, 
Frequency, and Severity 
scores, the nurse led 
educational intervention 
at the time of ablation, 
prior to discharge, and 
two weeks, one month, 
and three months post 
procedure had improved 







20, yet control 
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from one site 























Size & Setting 
Study findings that 





























new onset atrial 
fibrillation 
(within the past 
year) from 21 
countries  
- The University of 
Toronto Atrial 
Fibrillation Severity 
Scale (AFSS) was 
calibrated to the 
quantitative health 
related quality of life 
(HRQoL) in patients 
with atrial fibrillation, 
- Canadian 
Cardiovascular Society 
Severity in Atrial 
Fibrillation (CCS-SAF) 
scale utilized 
- An increase of 1 class 
in the CCS-SAF scale 
corresponds to a 3-point 
increase in AF symptom 
severity score on the 
AFSS 
 
- Risk for 
selection 














Size & Setting 
Study findings that 
























in the United States 
with atrial 
fibrillation  
- Symptom severity 
evaluated through 
application of the 
European Heart 
Rhythm Association 
(EHRA) scale  
- Quality of life 
correlated closely with 
symptom severity as 
measured by the 
EHRA class  
- Higher EHRA scores 
and lower quality of 
life were associated 
with higher risk for 
hospitalization  
- Findings 































Sample, Sample Size & 
Setting 
Study findings 
that help answer 












sub-study   
- 362 patients cared for at 
a designated heart 
rhythm/electrophysiology 
clinic in England  











Effect on Quality 
of Life (AFEQT), 

























Sample Size & 
Setting 
Study findings that 












- Men and 
women with 
one or more 
episodes of 
atrial fibrillation  
- 135 
individuals at a 
cardiology 
outpatient clinic 
in a tertiary 
hospital in 
Turkey  
-  EHRA classification 
and CCS-SAF scale both 
used  
- CCS-SAF applied to 
quantify functional 
impact of atrial 
fibrillation  
- EHRA applied to 
assess functional impact 
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Setting 
Study findings that 



















- 614 patients 
initially 
randomized to 
lenient or strict 
rate control  




RACE II setting: 
29 centers in the 
Netherlands   
- Symptom severity 
measured by the 
Toronto AF Severity 
Scale (AFSS) 

























Size & Setting 
Study findings that help 













- Men (65%) and 
women with an 
average age of 









Clinic at the 
University of 
North Carolina 
Chapel Hill  
 
- Canadian Cardiovascular 
Society Severity of Atrial 
Fibrillation (CCS-SAF) 
scale utilized to assess 
symptom severity  
- Individuals with limited 
or no symptoms based on 
implementation of the 
CCS-SAF can benefit 
from treatment of atrial 
fibrillation  
- Risk for 



































Sample Size & 
Setting 
Study findings that help 





















atrial fibrillation  
- 831 sites in 26 
countries   
 
-  European Heart 
Rhythm Association 
(EHRA) scale utilized for 
assessing AF-related 
symptom severity  
- Slightly lower 
proportion of individuals 
with symptoms with a 
rhythm strategy 
compared to a rate 
strategy for atrial 





























Size & Setting 
Study findings that 






9 Koci et al., 
2014 
Qualitative  - 224 Men (73.9%) 
and women 
enrolled from five 
different 
electrophysiologists 
at one center in 
Massachusetts  
- Implementation of a 
new classification 
scheme for symptom 
severity and burden 
associated with atrial 
fibrillation (Atrial 
Fibrillation Symptom 
and Burden, AFS/B)  
- Following statistical 
analysis, the AFS/B 
correlated well with 

















































Study findings that help 
















- Class I, Level C 
recommendation for use of 
the modified European 





















Sample Size & 
Setting 
Study findings that help 















- Atrial fibrillation specific 
instruments can be used to 
assess AF-related quality of 
life  
- Symptom based scales have 
limitations including 
comorbid conditions  
- The CCS-SAF scale and the 
EHRA classification score 
may be helpful for assessing 
impact of symptoms and 
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1. PubMed Symptom scale AND atrial 
fibrillation (118)  
None  5 2  
2. PubMed Canadian Cardiovascular 
Society AND atrial 
fibrillation (62)   
None 3 0 
3. PubMed  Canadian Cardiovascular 
Society AND Severity of 
atrial fibrillation (1) 
None  1 0 (no 
new 
articles)  
4. PubMed Symptom instrument AND 
cardiovascular (34)  
Publication dates- within five years 
(22)  
1 1  
5. PubMed Symptoms AND atrial 
fibrillation (40,327)  
Review (5,089); Date range 2016-
2017 (625); Free full text (186)  
 
3 1 
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Individual Evidence Summary Tool 
 












Size & Setting 
Findings that help 












-  Use of a symptom 
scale to assess the 
severity of atrial 
fibrillation 




simplicity to enhance 
utility” (p. 384) 
- Useful at assessing 
quality of life and well-
being (over-all impact 
of AF, not just when in 
it) 
- Incorporates side 
effects to 
medications/impact on 















Size & Setting 
Findings that help 











- 484 patients 
evaluated in 




- 67% men  
- 62% paroxysmal, 
38% 
persistent/permanent 
atrial fibrillation  
- CCS-SAF valid, but 
not reliable  
- CCS-SAF provides 
an objective 
assessment  
- Captures all aspects 
of atrial fibrillation  
- Not limited to 
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Findings that help 

















functional status for 
symptom burden and 
outcome measure  
- CCS-SAF allows 
identification of 
patients into classes, 
which can guide 
treatment  
- CCS-SAF intended 
for routine clinical 
use  
- CCS-SAF assess 
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instruments used for 
cardiovascular 
populations 
- The CCS-SAF scale 
is valid, specific, 
multi-dimensional, 
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Canadian Cardiovascular Society  
 
Severity of Atrial Fibrillation (SAF) Scale 
 
 
Step 1 – Symptoms 
Identify the presence of the following symptoms:  
Palpitation 
Dyspnea 
Dizziness, presyncope, or syncope Chest pain 
Weakness or fatigue  
Step 2 – Association 
Is AF, when present, associated with the above-listed symptoms (A-E)?  
For example: Ascertain if any of the above symptoms are present during AF and likely caused by 
AF (as opposed to some other cause).  
Step 3 – Functionality 
Determine if the symptoms associated with AF (or the treatment of AF) affect the  
patient’s functionality (subjective quality of life).  
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CCS-SAF Class Definitions  
Class 0  
Asymptomatic with respect to AF  
Class 1  
Symptoms attributable to AF have minimal effect on patient’s general QOL.  
• minimal and/or infrequent symptoms, or  
• single episode of AF without syncope or heart failure  
 
Class 2  
Symptoms attributable to AF have a minor effect on patient’s general QOL.  
 mild awareness of symptoms in patients with persistent/permanent AF, or  
 rare episodes (e.g. less than a few per year) in patients with paroxysmal or intermittent 
AF  
Class 3  
Symptoms attributable to AF have a moderate effect on patient’s general QOL.  
 moderate awareness of symptoms on most days in patients with  
persistent/permanent AF, or  
 more common episodes (e.g. more than every few months) or more severe symptoms, or 
both, in patients with paroxysmal or intermittent AF  
 
Class 4  
Symptoms attributable to AF have a severe effect on patient’s general QOL.  
 very unpleasant symptoms in patients with persistent/paroxysmal AF and/or  
 frequent and highly symptomatic episodes in patients with paroxysmal or intermittent AF 
and/or  
 syncope thought to be due to AF and/or  
 congestive heart failure secondary to AF  
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(2009). Validation of a new simple scale to measure symptoms in atrial fibrillation: The 
Canadian Cardiovascular Society severity in atrial fibrillation scale. Circulation: 
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Appendix G  
 
ST CATHERINE UNIVERSITY  
 
Information Regarding Proposed Project  
 
You are invited to participate in the project, “Implementing an Atrial Fibrillation Symptom 
Severity Scale to Assist with Management within the Subspecialty of Electrophysiology at the 
Minneapolis Heart Institute.”  The project will be implemented by Allison Helland Sill, a 
doctoral nursing candidate at St. Catherine University in St. Paul, MN.  The faculty advisor for 
this project is Gwen Short, DNP, MPH, APRN, FNP through the St. Catherine University 
Graduate Nursing program.  The site advisor for this project is Jay Sengupta, MD.   
 
The purpose of this project is to evaluate the impact implementation of the Canadian 
Cardiovascular Society Severity of Atrial Fibrillation (CCS-SAF) scale has on developing a 
treatment plan, evaluating response to treatment, and enhancing communication.  This project is 
important because symptom assessment is a cornerstone for managing atrial fibrillation (Koci et 
al., 2014).  Not only do symptoms give insight into the impact on quality of life, but they also 
assist with monitoring response to treatment interventions (Koci et al., 2014).  With the 
increasing prevalence of individuals with atrial fibrillation, the need for adequate management 
will continue to grow (Koci et al., 2014).   
 
Below, you will find answers to the most commonly asked questions about participating in this 
project.   
 
Why have I been asked to participate? 
 
Secondary to the high number of individuals with atrial fibrillation evaluated by the 
electrophysiology group at the Minneapolis Heart Institute, this population will provide 
beneficial feedback regarding the utility of the CCS-SAF scale.   
 
If I decide to participate, what will I be asked to do? 
 
 Participate in a pre-implementation online survey and PowerPoint presentation 
addressing the proposed project.  This is estimated to take approximately 30 minutes.  
 Implement the CCS-SAF scale for all individuals evaluated in the clinic with a primary 
visit diagnosis of atrial fibrillation (including paroxysmal, persistent, longstanding 
persistent, and permanent).  The time commitment for this will vary depending on the 
population of individuals with atrial fibrillation.  The estimated time to complete and 
document the CCS-SAF numeric category should be less than two minutes per patient.   
 There will be a post-implementation survey after week eight.  This is an online survey 
and is estimated to take less than 10 minutes.  
In total, this project will take approximately 184 minutes for providers at the Minneapolis, Edina, 
Plymouth (WestHealth), and Chaska locations.  There will be one initial session, which will 
include a pre-implementation survey and PowerPoint presentation.  The last session will include 
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a 10 minute post-implementation survey.  The remainder of the time will be spent completing 
and documenting the CCS-SAF numeric category in the objective section of the clinic progress 
note.   
 
What if I decide I do not want to be involved? 
 
Participation is completely voluntary.  If you decide you do not want to participate, please do not 
complete the pre-implementation survey.  Completion of the pre-implementation survey implies 
that you agree to participate.  Your decision of whether to participate will have no negative or 
positive impact on your relationship with St. Catherine University. 
 
What are the risks of participation? 
 
Risks include variability in scoring of the CCS-SAF scale.  The scale is provider-administered 
and thus open to subjectivity.  This may result in some providers rating an individual’s severity 
class higher than a colleague.  A higher score indicates worsening impact on quality of life 
(Dorian et al., 2009) and more aggressive management options with higher potential for 
complications may ensue.     
 
Another concern is breach of confidentiality when completing the online surveys.  Given the 
small population size, if de-identification is not completed properly, confidentiality could be 
jeopardized.  
 
What are the potential benefits of the project?  
 
The direct benefit for participating in implementation of the CCS-SAF scale is providing an 
enhanced ability to quickly identify severity of symptoms associated with atrial fibrillation 
through a semi-quantitative scale.  The goal of implementation is to have a consistent method for 
assessing the impact atrial fibrillation has on an individual’s quality of life, assist with 
developing a treatment plan, enhance communication, put in context the risks and benefits of 
various medical and procedural options, and contribute to research (Aliot, Botto, Crijns, & 
Kirchhof, 2014; Dorian et al., 2009). 
 
Societal benefits include consistent symptom identification, which is as a cornerstone for the 
management of atrial fibrillation (Koci et al., 2014).  The long-term goal is to disseminate use to 
providers within general cardiology, other cardiovascular subspecialties, and internal medicine.  
This will assist in identifying when adjustments to the treatment regimen are needed or whether 
to consider referral.  
 
Will I receive any compensation for participating? 
 
A gift card to Peace Coffee for the value of $25 will be granted at the end of the project in 
recognition of participation.  
 
What will you do with the information you get and how will you protect my privacy? 
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The information that you provide will be de-identified and transferred to a numeric value.  Only 
the principal investigator and site advisor will have access to the key.  This form will be entered 
in an Excel document, which will require a password for access.  The principal investigator will 
finish analyzing the data by April of 2018, after which all original reports and identifying 
information that can be linked back to you will be destroyed no later than June of 2018. 
 
Any information that you provide will be kept confidential, which means that you will not be 
identified or identifiable in any written reports or publications.  If it becomes useful to disclose 
any of your information, the principal investigator will seek your permission and tell you the 
persons or agencies to whom the information will be furnished, the nature of the information to 
be furnished, and the purpose of the disclosure; you will have the right to grant or deny 
permission for this to happen.  If you do not grant permission, the information will remain 
confidential and will not be released. 
 
Are there possible changes to the project once it gets started? 
 
If during implementation of this project the principal investigator learns about new findings that 
might influence your willingness to continue participating, you will be updated on these findings.  
 
How can I get more information? 
 
If you have any questions, feel free to contact the principal investigator at the following email 
address, allison.sill@allina.com.  If you have any additional questions later and would like to 
talk to the faculty advisor, please contact Dr. Gwen Short at gsshort@stkate.edu.  If you have 
other questions or concerns regarding the project and would like to talk to someone other than 
the investigator, you may also contact Dr. John Schmitt, Chair of the St. Catherine University 
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Q7 How could the scale be more easily integrated into the
documentation?
Answered: 6 Skipped: 2
# RESPONSES DATE
1 .phrase 2/7/2018 10:32 AM
2 Include with intake form filled out by new patients 2/5/2018 7:41 PM
3 I realize that I don't know the dot phrase or what to write. 1/31/2018 2:18 PM
4 dot phrase (for inpatient). more difficult for outpatients that are dicatated. 1/30/2018 12:36 PM
5 more automated into Epic 1/30/2018 11:32 AM
6 An enlarged copy posted in each workroom might help- to use as a reference. Mostly it's just a











Q8 Comments or concerns regarding use of the CCS-SAF scale 
Answered: 4 Skipped: 4
# RESPONSES DATE
1 more guidelines needed to connect scale with pathophysiology of disease 2/7/2018 10:32 AM
2 Same as above 1/31/2018 2:18 PM
3 Only used for a short period of time (so at most, one time for any given patient). Would be more
meaningful after longer follow-up periods (eg to assess trend in CCS-SAF scale after multiple
follow-up visits/interventions)
1/30/2018 12:36 PM
4 I think it's a great idea to have a common way to assess symptoms. The scale is fairly easy to use.
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Appendix J  
 





















































Qualify 4 9 16 11 16 5 12 8 2 13 10 10 5 8 13 12 18 7 8 15 16 22 9 
Completed 0 0 0 0 0 0 1 6 0 4 0 5 0 0 0 0 0 0 0 0 0 7 0 
 
Red = CCS-SAF incorporated into notes section on schedule 
